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Abstract
Background: Carbon monoxide (CO) synthesized by heme oxygenase 1 (HO-1) exerts antinociceptive effects during
inflammation but its role during neuropathic pain remains unknown. Our objective is to investigate the exact contribution
of CO derived from HO-1 in the modulation of neuropathic pain and the mechanisms implicated.
Methodology/Principal Findings: We evaluated the antiallodynic and antihyperalgesic effects of CO following sciatic nerve
injury in wild type (WT) or inducible nitric oxide synthase knockout (NOS2-KO) mice using two carbon monoxide-releasing
molecules (CORM-2 and CORM-3) and an HO-1 inducer (cobalt protoporphyrin IX, CoPP) daily administered from days 10 to
20 after injury. The effects of CORM-2 and CoPP on the expression of HO-1, heme oxygenase 2 (HO-2), neuronal nitric oxide
synthase (NOS1) and NOS2 as well as a microglial marker (CD11b/c) were also assessed at day 20 after surgery in WT and
NOS2-KO mice. In WT mice, the main neuropathic pain symptoms induced by nerve injury were significantly reduced in
a time-dependent manner by treatment with CO-RMs or CoPP. Both CORM-2 and CoPP treatments increased HO-1
expression in WT mice, but only CoPP stimulated HO-1 in NOS2-KO animals. The increased expression of HO-2 induced by
nerve injury in WT, but not in NOS2-KO mice, remains unaltered by CORM-2 or CoPP treatments. In contrast, the over-
expression of CD11b/c, NOS1 and NOS2 induced by nerve injury in WT, but not in NOS2-KO mice, were significantly
decreased by both CORM-2 and CoPP treatments. These data indicate that CO alleviates neuropathic pain through the
reduction of spinal microglial activation and NOS1/NOS2 over-expression.
Conclusions/Significance: This study reports that an interaction between the CO and nitric oxide (NO) systems is taking
place following sciatic nerve injury and reveals that increasing the exogenous (CO-RMs) or endogenous (CoPP) production
of CO may represent a novel strategy for the treatment of neuropathic pain.
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Introduction
Neuropathic pain is a clinical manifestation characterized by the
presence of allodynia and hyperalgesia and it is difficult to treat
with the most potent analgesic compounds. The mechanisms
contributing to this syndrome involve local inflammatory re-
sponses, changes in the plasticity of neuronal nociceptive pathways
and activation of spinal microglia [1].
Nitric oxide (NO) synthesized either by neuronal (NOS1) or
inducible (NOS2) nitric oxide synthase mediates numerous
neuropathic pain symptoms via cGMP-PKG pathway activation
[2–4]. Accordingly, the expression of both enzymes is up-regulated
in the spinal cord and dorsal root ganglia of animals with
neuropathic pain [5–7]. The hypersensitivity effects induced by
nerve injury are significantly diminished or absent in NOS1
(NOS1-KO) and NOS2 (NOS2-KO) knockout animals [6,8] or
reversed by the administration of selective NOS, guanylate cyclase
or PKG inhibitors [4,5,9]. Moreover, the intraperitoneal admin-
istration of a NO donor potentiates the mechanical and thermal
hypersensitivity induced by neuropathic pain [10].
Carbon monoxide (CO) synthesized by heme oxygenases-1
(HO-1) or 2 (HO-2), is another gaseous neurotransmitter
implicated in the modulation of nociceptive pathways. However,
while HO-2 exerts a pronociceptive effect during neuropathic pain
[11], HO-1 plays an important role in the modulation of acute
inflammatory pain [12,13]. Consequently, the expression of HO-2
increases after nerve injury and the mechanical and thermal
hypersensitivity to pain induced by nerve injury has been shown to
be markedly decreased in HO-2-KO mice [14,15]. In contrast, the
over-expression of HO-1 is associated with potent anti-inflamma-
tory and antinociceptive effects during inflammatory pain [11,12].
However, the exact contribution of CO synthesized by HO-1 in
the modulation of the main symptoms of neuropathic pain
induced by sciatic nerve injury remains unknown.
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It is interesting to note that, similarly to NO, CO also activates
the cGMP-PKG pathway. As a result, a cross-talk has been
reported between these two gases in several in vitro and in vivo
models. For instance, NOS2-derived NO as well as NO donors
contribute to induction of HO-1 by cGMP-PKG-dependent
pathway activation [16], indicating that NO is an important
regulator of CO produced by HO-1 [17–19]. Studies in vivo also
demonstrated that while the antihyperalgesic effects induced by
CO depend on the integrity of the NOS pathways, the
antinociceptive responses produced by NO are independent of
CO [13]. Nevertheless, the possible interaction between the NO
and CO systems during neuropathic pain has not been in-
vestigated.
Carbon monoxide-releasing molecules (CO-RMs) are a new
class of chemical agents able to reproduce numerous biological
effects of HO-1-derived CO [20–23]. Several authors has shown
that CO-RMs and HO-1 induction using cobalt protoporphyrin
IX (CoPP) exert potent anti-inflammatory effects in vivo [11,24].
However, the possible antiallodynic and antihyperalgesic effects
produced by these compounds during neuropathic pain have not
been evaluated.
It is well known that microglia modulates several neuronal
changes occurring during the development and maintenance of
numerous chronic states, including neuropathic pain [1,25].
Interestingly, the administration of inhibitors of microglial cells
activation significantly reduces the behavioral symptoms of
neuropathic pain [25]. Thus, we investigated the potential role
of CO and HO-1-derived CO in the modulation of neuropathic
pain as well as the possible mechanisms involved in this action.
Specifically, in sciatic nerve-injured WT and NOS2-KO mice we
evaluated: 1) the mechanical antiallodynic, thermal antihyper-
algesic and thermal antiallodynic effects produced by the
administration of two CO-RMs, tricarbonyldichlororuthrnium(II)
dimer (CORM-2) and tricarbonylchloro (glycinate)ruthenium (II)
(CORM-3) as well as a classical HO-1 inducer (CoPP) and 2) the
effect of these treatments on the expression of HO and NOS
isoforms as well as CD11b/c, a marker of microglia activation, in
the dorsal root ganglia and spinal cord of these animals.
Results
Effect of CORM-2, CORM-3 and CoPP Treatments in WT
and NOS2-KO Sciatic Nerve-injured Mice
Animals were intraperitoneally administered twice daily with
CORM-2 (5 mg/kg), CORM-3 (5 mg/kg), CoPP (2.5 mg/kg) or
vehicle for a period of 11 days after surgery. On days 1, 5 and 11
of treatment mice were sequentially assessed for mechanical
allodynia, thermal hyperalgesia and thermal allodynia.
Sciatic nerve injury led to a significant decrease of the threshold
for evoking hind paw withdrawal to a mechanical stimulus in WT
animals (Fig. 1A) which response was abolished in NOS2-KO
mice (Fig. 1D). That is, mechanical allodynia was developed in
vehicle treated WT mice exposed to sciatic nerve injury from days
10 to 20 after surgery when compared to sham-operated mice
(p,0.001; one way ANOVA). This mechanical allodynia was
significantly attenuated in nerve-injured WT mice repeatedly
treated with CORM-2, CORM-3 or CoPP (Fig. 1A). The three-
way ANOVA revealed a significant effect of the surgery, treatment
and time (p,0.001) and a significant interaction between
treatment and time (p,0.001), surgery and treatment (p,0.001),
surgery and time (p,0.001) and between surgery, treatment and
time (p,0.001). Indeed, mechanical allodynia was equally reduced
on day 1 in CORM-2 and CORM-3, but not in CoPP, treated
mice (p,0.001; one way ANOVA vs. vehicle nerve-injured treated
mice), although the antiallodynic efficacy of all of them increased
progressively on days 5 and 11 of treatment (p,0.001; one way
ANOVA vs. vehicle nerve-injured treated mice). In sham-operated
WT mice CORM-2, CORM-3 and CoPP treatments did not
produce any effect as compared to sham-operated vehicle treated
WT mice for the whole duration of the experiment.
The effects of CORM-2, CORM-3 or CoPP treatments in
NOS2-KO mice exposed to sciatic nerve injury have been also
evaluated. The three-way ANOVA did not reveal any significant
effect of the surgery, treatment and time and non significant
interaction between theme was demonstrated. Mechanical allo-
dynia was not developed in NOS2-KO mice and the systemic
administration of CORM-2, CORM-3 or CoPP did not alter the
lack of mechanical allodynia observed in these nerve-injured
animals (Fig. 1D). Sham operation did not produce any effect
neither in CORM-2, CORM-3 or CoPP nor in vehicle treated
NOS2-KO mice for the whole duration of the experiment.
Sciatic nerve injury led to a significant decrease of the threshold
for evoking paw withdrawal to a thermal stimulus in WT mice
from days 10 to 20 after surgery as compared to sham-operated
mice (p,0.001; one way ANOVA). This thermal hyperalgesia was
significantly attenuated in nerve-injured WT mice repeatedly
treated with CORM-2, CORM-3 or CoPP (Fig. 1B). The three-
way ANOVA revealed a significant effect of the surgery, treatment
and time (p,0.001) and a significant interaction between
treatment and time (p,0.001), surgery and treatment (p,0.001),
surgery and time (p,0.001) as well as between surgery, treatment
and time (p,0.001). Indeed, thermal hyperalgesia was completely
blocked on day 1 in CORM-2 and CORM-3 treated WT mice
(p,0.001; one way ANOVA vs. vehicle nerve-injured treated
mice) and this level of efficacy was similarly maintained for both
compounds on days 5 and 11 of treatment (p,0.001; one way
ANOVA vs. vehicle nerve-injured treated mice). In contrast,
thermal hyperalgesia was only significantly reduced by CoPP on
day 5 (p,0.001; one way ANOVA vs. vehicle nerve-injured
treated mice) and its antihyperalgesic efficacy increased pro-
gressively on day 11 of treatment (p,0.001; one way ANOVA vs.
vehicle nerve-injured treated mice). In sham-operated WT mice
CORM-2, CORM-3 and CoPP treatments did not produce any
effect as compared to sham-operated vehicle treated WT mice for
the whole duration of the experiment.
The effects of CORM-2, CORM-3 or CoPP treatments in
NOS2-KO mice after sciatic nerve injury have been also
evaluated. The three-way ANOVA did not reveal any significant
effect of the surgery, treatment and time and non significant
interaction between theme was demonstrated. Thermal hyper-
algesia was not developed in NOS2-KO mice and the systemic
administration of CO-RM’s or CoPP did not alter the absence of
thermal hypersensitivy observed in these nerve-injured NOS2-KO
animals (Fig. 1E). Sham operation did not produce any effect
neither in CORM-2, CORM-3 or CoPP nor in vehicle treated
NOS2-KO mice for the whole duration of the experiment.
Sciatic nerve injury increased the number of ipsilateral paw lifts
during cold thermal stimulation in WT mice from days 10 to 20
after surgery as compared to sham-operated WT mice (p,0.001;
one way ANOVA). This thermal allodynia was significantly
attenuated in nerve-injured WT mice repeatedly treated with
CORM-2, CORM-3 or CoPP (Fig. 1C). The three-way ANOVA
revealed a significant effect of the surgery (p,0.001), treatment
(p,0.001) and time (p,0.010) as well as a significant interaction
between treatment and time (p,0.013), surgery and treatment
(p,0.022), surgery and time (p,0.001) and the triple interaction
between surgery, treatment and time (p,0.014). Indeed, although
thermal allodynia was similarly reduced on days 1 and 5 in
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CORM-2 and CORM-3, but not in CoPP, treated WT mice
(p,0.001; one way ANOVA vs. vehicle nerve-injured treated
mice) the antiallodynic efficacy of all treatments increased
progressively on day 11, where thermal allodynia was completely
blocked by CORM-2, CORM-3 or CoPP treatments (p,0.001;
one way ANOVA vs. vehicle nerve-injured treated mice). In sham-
operated WT mice CORM-2, CORM-3 or CoPP treatments did
not produce any effect as compared to sham-operated vehicle
treated WT animals for the whole duration of the experiment.
The effects of CORM-2, CORM-3 or CoPP treatments in
NOS2-KO mice after sciatic nerve injury have been also
evaluated. The three-way ANOVA did not reveal any significant
effect of the surgery, treatment and time and non significant
interaction between theme was demonstrated. Thermal allodynia
was not developed in NOS2-KO mice and the systemic
administration of CORM-2, CORM-3 or CoPP did not alter
the absence of thermal allodynia observed in these NOS2-KO
nerve-injured animals (Fig. 1F). Sham operation did not produce
any effect neither in CORM-2, CORM-3 or CoPP nor in vehicle
treated NOS2-KO mice for the whole duration of the experiment.
In all experiments, CORM-2, CORM-3 or CoPP treatments
did not have any significant effect in the contralateral paw of
sciatic nerve-injured or sham-operated WT or NOS2-KO animals
(data not shown).
Effect of CORM-2 and CoPP on HO-1 and HO-2 Protein
Expression in the Dorsal Root Ganglia and Spinal Cord
from WT and NOS2-KO Sciatic Nerve-injured Mice
The protein levels of HO-1 in the dorsal root ganglia (A) and
spinal cord (B) from sciatic nerve-injured WT or NOS2-KO mice
treated with vehicle, CORM-2 or CoPP are shown in Fig. 2. For
each tissue, the expression of HO-1 from sham-operated WT or
NOS2-KO vehicle treated mice has been also shown. In both
tissues, non-significant differences were found between genotypes
as compared to the expression of HO-1 among them in vehicle
sham-operated or vehicle sciatic nerve-injured mice treated with
vehicle. However, while in sciatic nerve-injured WT mice the
dorsal root ganglia and spinal cord expression of HO-1 was
significantly increased by CORM-2 or CoPP treatments
(p,0.001; one-way ANOVA vs. sham-operated and nerve-injured
vehicle treated WT mice), in NOS2-KO mice the expression of
this enzyme was only enhanced by CoPP (p,0.001; one-way
ANOVA vs. to the other groups). In addition, the enhanced
Figure 1. Effect of CORM-2, CORM-3 and CoPP on sciatic nerve-injured WT and NOS2-KO mice. The development of the mechanical
allodynia (A and D), thermal hyperalgesia (B and E) and thermal allodynia (C and F) in sciatic nerve-injured (continuous lines) and sham-operated
(discontinuous lines) WT or NOS2-KO mice treated during 11 consecutive days with vehicle, CORM-2, CORM-3 or CoPP at 10, 14 and 20 days after
surgery is shown. For each genotype, test, day and drug evaluated, *indicates significant differences when compared vs. vehicle sham-operated
group (p,0.001, one-way ANOVA followed by the Student Newman Keuls test) and +indicates significant differences when compared vs. vehicle
nerve-injured group (p,0.001, one-way ANOVA followed by the Student Newman Keuls test). Results are shown as mean values6 SEM; n = 7 animals
per experimental group.
doi:10.1371/journal.pone.0043693.g001
Figure 2. Effect of CORM-2 and CoPP on HO-1 protein expression from sciatic nerve-injured WT and NOS2-KO mice. The protein
expression in the ipsilateral site of the dorsal root ganglia (A) and the lumbar section of the spinal cord (B) from sciatic nerve-injured (CCI) WT and
NOS2-KO mice treated with vehicle, CORM-2 or CoPP at 20 days after surgery is represented. The expression of HO-1 in the dorsal root ganglia and
spinal cord from sham-operated WT and NOS2-KO mice treated with vehicle has been also represented as controls (sham-vehicle). In both figures and
genotypes, *indicates significant differences when compared vs. their respective sham-operated vehicle treated mice (*p,0.05, one-way ANOVA
followed by the Student Newman Keuls test), +indicates significant differences when compared vs. their respective sciatic nerve-injured vehicle
treated mice (+p,0.05, one-way ANOVA followed by the Student Newman Keuls test), #indicates significant differences when compared vs. their
respective sciatic nerve-injured CORM-2 treated mice (#p,0.05, one-way ANOVA followed by the Student Newman Keuls test). Representative
examples of western blots for HO-1 protein (32 kDa) in which b-actin (45 kDa) was used as a loading control are also shown. Data are expressed as
mean values 6 SEM; n = 5 samples per group.
doi:10.1371/journal.pone.0043693.g002
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expression of HO-1 induced by CoPP in the dorsal root ganglia
and spinal cord of sciatic nerve-injured WT mice is higher than
those produced by CORM-2 treatment (p,0.001; one-way
ANOVA followed by Student Newman Keuls test).
The protein levels of HO-2 in the dorsal root ganglia (A) and
spinal cord (B) from sciatic nerve-injured WT or NOS2-KO mice
treated with vehicle, CORM-2 or CoPP are shown in Fig. 3. The
expression of HO-2 from sham-operated WT or NOS2-KO mice
treated with vehicle is also shown. Sciatic nerve injury significantly
increased the dorsal root ganglia and spinal cord levels of HO-2 in
vehicle, CORM-2 and CoPP treated WT mice (p,0.001; one-way
ANOVA vs. sham-operated vehicle treated WT mice). In contrast,
the dorsal root ganglia and spinal cord expression of HO-2 was
not altered in vehicle, CORM-2 and CoPP treated nerve-injured
NOS2-KO mice.
Effect of CORM-2 and CoPP on CD11b/c Protein
Expression in the Spinal Cord from WT and NOS2-KO
Sciatic Nerve-injured Mice
We next investigated whether the increased spinal cord
expression of CD11b/c induced by nerve injury was altered by
CORM-2 and CoPP treatments. The expression of CD11b/c
from sham-operated WT or NOS2-KO vehicle treated mice is
also evaluated (Fig. 4). Our results showed that the repeated
treatment with CORM-2 and CoPP inhibited the increased
expression of CD11b/c induced by sciatic nerve injury in WT
mice (p,0.001; one-way ANOVA vs. sham-operated WT mice).
Interestingly, sciatic nerve injury did not increase the protein levels
of CD11b/c in NOS2-KO mice, which expression remains
unaltered after CORM-2 or CoPP treatment.
Effect of CORM-2 and CoPP on NOS1 and NOS2 Protein
Expression in the Spinal Cord from WT and NOS2-KO
Sciatic Nerve-injured Mice
The protein levels of NOS1 (A) and NOS2 (B) in the spinal cord
from sciatic nerve-injured WT or NOS2-KO mice treated with
vehicle, CORM-2 or CoPP are shown in Fig. 5. The expression of
NOS1 and NOS2 from sham-operated WT or NOS2-KO mice
treated with vehicle has been also shown. Sciatic nerve injury
significantly increased the protein levels of NOS1 and NOS2 in
the spinal cord of WT mice (p,0.001; one-way ANOVA vs.
sham-operated vehicle treated WT mice), which levels were
significantly reduced by the repeated intraperitoneal administra-
tion of CORM-2 and CoPP. In contrast, sciatic nerve injury did
not alter the spinal cord expression of NOS1 as well as of NOS2 in
vehicle, CORM-2 or CoPP treated NOS2-KO animals, which
protein levels were similar to those obtained in sham-operated
NOS2-KO mice.
A summary of the results from the protein expression studies
obtained in the ipsilateral site of the dorsal root ganglia and/or the
lumbar section of the spinal cord from sciatic nerve-injured WT
and NOS2-KO mice treated with vehicle, CORM-2 or CoPP is
shown in Table 1.
Discussion
In the present study we demonstrated, for first time, that the
repeated intraperitoneal administration of CORM-2, CORM-3 or
CoPP significantly reduced the mechanical allodynia, thermal
hyperalgesia and thermal allodynia induced by the chronic
constriction of sciatic nerve in WT mice. Our results also indicate
that these effects are mainly produced by CO synthesized by HO-
Figure 3. Effect of CORM-2 and CoPP on HO-2 protein expression from sciatic nerve-injured WT and NOS2-KO mice. The protein
expression in the ipsilateral site of the dorsal root ganglia (A) and the lumbar section of the spinal cord (B) from sciatic nerve-injured (CCI) WT and
NOS2-KO mice treated with vehicle, CORM-2 or CoPP at 20 days after surgery is represented. The expression of HO-2 in the dorsal root ganglia and
spinal cord from sham-operated WT and NOS2-KO mice treated with vehicle has been also represented as controls (sham-vehicle). In both figures and
genotypes, *indicates significant differences when compared vs. their respective sham-operated vehicle treated mice (*p,0.05, one-way ANOVA
followed by the Student Newman Keuls test). Representative examples of western blots for HO-2 protein (37 kDa) in which b-actin (45 kDa) was used
as a loading control are also shown. Data are expressed as mean values 6 SEM; n = 5 samples per group.
doi:10.1371/journal.pone.0043693.g003
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1, through reduction of spinal microglial activation and NOS1/
NOS2 over-expression.
It is well known that CO has potent antinociceptive and anti-
inflammatory effects during inflammatory diseases [12,24,26]. In
accordance, the results presented here further demonstrate that
the intraperitoneal administration of CO by using CORM-2 and
CORM-3 as well as the induction of endogenous CO by injection
of the HO-1 inducer CoPP during 11 consecutive days signifi-
cantly reduced the mechanical and thermal hypersensitivity
induced by sciatic nerve injury in WT mice. Our results also
revealed that, although at 11 days of treatment all compounds
inhibited neuropathic pain with similar effectiveness, the anti-
allodynic and antihyperalgesic effects produced by CORM-2 and
CORM-3 on days 1 and 5 of treatment were significantly higher
than those produced by CoPP. These results could be related to
the more direct release of CO by CO-RMs, in contrast to the HO-
1 over-expression required by CoPP to synthesize CO. Our data
also indicate that CO-RMs are more effective on the inhibition of
thermal hyperalgesia than of mechanical and thermal allodynia
induced by sciatic nerve injury.
In accordance to our previous studies [6], our findings showed
that the principal manifestations of neuropathic pain induced by
sciatic nerve injury were completely abolished in NOS2-KO mice.
In addition, the lack of thermal and mechanical hypersensitivity
observed in sciatic nerve-injured NOS2-KO mice remained
unchanged after CO-RMs or CoPP treatments, similarly to that
occurs in sham-operated WT or NOS2-KO treated animals.
As previously shown in other inflammatory models [27,28], our
results also demonstrated that the expression of HO-1 was
significantly increased in the dorsal root ganglia and spinal cord
of sciatic nerve-injured WT mice treated with CORM-2 or CoPP.
As expected, the enhanced expression of HO-1 induced by CoPP
(a HO-1 expression inducer) was higher than those produced by
CORM-2 treatment. Interestingly, in sciatic nerve-injured NOS2-
KO mice the expression of HO-1 was only increased after CoPP
treatment. These results indicate that CORM-2 requires the
presence of NOS2 to enhance the expression of HO-1, revealing
that NO plays a key role in the positive feedback regulation of
HO-1 over-expression during neuropathic pain. In accordance to
our results other studies have been also demonstrated that the
antihyperalgesic effects induced by CO in acute pain depend on
the integrity of NO pathway [13].
In contrast to HO-1-derived CO, CO synthesized by HO-2
contributes to the progression of neuropathic pain. Thus, the lack
of HO-2 appears to prevent the mechanical and thermal
hypersensitivity to pain induced by nerve injury and the expression
of this enzyme increases during neuropathic pain [14,15,29]. Our
data support these findings and also demonstrate that the
Figure 4. Effect of CORM-2 and CoPP on CD11b/c protein expression from sciatic nerve-injured WT and NOS2-KO mice. The protein
expression in the ipsilateral site of the lumbar section of the spinal cord from sciatic nerve-injured (CCI) WT and NOS2-KO mice treated with vehicle,
CORM-2 or CoPP at 20 days after surgery is represented. The expression of CD11b/c in the spinal cord from sham-operated WT and NOS2-KO mice
treated with vehicle has been also represented as controls (sham-vehicle). In this figure *indicates significant differences when compared vs. sham-
operated vehicle treated WT mice (*p,0.05, one-way ANOVA followed by the Student Newman Keuls test). Representative examples of western blots
for CD11b/c protein (97 kDa) in which b-actin (45 kDa) was used as a loading control are also shown. Data are expressed as mean values6 SEM; n = 5
samples per group.
doi:10.1371/journal.pone.0043693.g004
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increased expression of this isoenzyme in the dorsal root ganglia
and spinal cord of sciatic nerve-injured WT mice is not altered by
CORM-2 or CoPP treatments, indicating that the antiallodynic
and antihyperalgesic effects produced by the chronic administra-
tion of both compounds are not produced by the inhibition of the
enhanced peripheral or central expression of HO-2 induced by
nerve injury. In addition, the fact that the expression of HO-2 did
not increase in the spinal cord and dorsal root ganglia of sciatic
nerve-injured NOS2-KO mice, provide evidence that the up-
regulation of HO-2 induced by nerve injury required the presence
of NOS2, further supporting the relevant interactions between
NOS/NO and HO/CO pathways previously demonstrated in
other in vivo and in vitro models [11].
The molecular mechanism implicated in the inhibitory effects
produced by CO after neuropathic pain is currently unknown. It
has been reported that nerve injury promotes the activation of
spinal glial cells, and that this activated glia may contribute to the
initiation and maintenance of neuropathic pain [30]. Indeed, the
administration of inhibitors of microglial cells activation signifi-
cantly reduced the behavioral symptoms of neuropathic pain [25].
Several studies also demonstrated the presence of HO-1 in glial
cells [31], but the possible effect of CO liberated by CORM-2 or
synthesized by HO-1 on the modulation of activated microglia
induced by nerve injury is not yet well established. Thus, in order
to evaluate if this gas could reduce microglial activation and to
establish the role played by NO, synthesized by NOS1 and NOS2,
in this process we evaluated the expression of CD11b/c (as
a measure of microglial activation), as well as of NOS1 and NOS2
in the spinal cord of sciatic nerve-injured WT mice treated with
CORM-2 or CoPP. It is interesting to note that CORM-2 and
CoPP treatments reduced the spinal microglial activation as well
as the enhanced NOS1 and NOS2 expression induced by sciatic
nerve injury in WT mice. Thus, the alleviation of the behavioral
manifestations of neuropathic pain in CO-RMs or CoPP-treated
WT animals could be due to the inhibition of inflammatory
responses that are linked to the microglia activation in the spinal
cord. In contrast to WT mice, the expression of CD11b/c and
NOS1 remains unaltered after nerve injury in NOS2-KO mice
and neither CORM-2 nor CoPP treatment had any effect in these
animals. These results support the hypothesis that the activation of
NOS/NO pathway promotes the activation of microglia and
Figure 5. Effect of CORM-2 and CoPP on NOS1 and NOS2 protein expression from sciatic nerve-injured WT and NOS2-KO mice. The
protein expression in the ipsilateral site of the lumbar section of the spinal cord of NOS1 (A) and NOS2 (B) from sciatic nerve-injured (CCI) WT and
NOS2-KO mice treated with vehicle, CORM-2 or CoPP at 20 days after surgery is represented. The expression of NOS1 and NOS2 in the spinal cord
from sham-operated WT and NOS2-KO mice treated with vehicle has been also represented as controls (sham-vehicle). In both figures and genotypes,
*indicates significant differences when compared vs. their respective sham-operated vehicle treated mice (*p,0.05, one-way ANOVA followed by the
Student Newman Keuls test). Representative examples of western blot for NOS1 (155 kDa) and NOS2 (130 kDa) proteins in which b-actin (45 kDa)
was used as a loading control are also shown. Data are expressed as mean values 6 SEM; n = 5 samples per group.
doi:10.1371/journal.pone.0043693.g005
Table 1. A summary of the results from protein expression
studies obtained in the ipsilateral site of the dorsal root
ganglia (DRG) and/or the lumbar section of the spinal cord
(SC) from sciatic nerve-injured (CCI) WT and NOS2-KO mice
treated with vehicle, CORM-2 or CoPP is shown.
WT NOS2-KO
CCI CCI CCI CCI CCI CCI
Protein Tissue Vehicle CORM-2 CoPP vehicle CORM-2 CoPP
HO-1 DRG R q qq R R qq
SC R q qq R R qq
HO-2 DRG q q q R R R
SC q q q R R R
CD11b/c SC q R R R R R
NOS1 SC q R R R R R
NOS2 SC q R R R R R
The arrows indicate: R unchanged, q increased and qq more increased
expression as compared to the expression obtained in their corresponding
sham-operated animals treated with vehicle.
doi:10.1371/journal.pone.0043693.t001
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contributes to the behavioral pain responses evoked by nerve
injury, as previously demonstrated by the lack or reduced
mechanical and thermal hypersensitivity induced by nerve injury
in NOS2-KO mice [6,8].
Recent studies indicate that CORM-2, but not CORM-3, is
also an antagonist of P2X4 receptors [32] and it is well known that
the up-regulation of these receptors in microglia is an important
process in producing neuropathic pain [33]. However, the similar
behavioral inhibitory effects produced by CORM-2 and CORM-3
in the present study indicate that P2X4 receptors are not the main
molecular targets for the antinociceptive effects produced by
CORM-2 under neuropathic pain conditions. The modulation of
neuropathic pain by the HO-1/CO pathway after sciatic nerve
injury could be explained by the inhibition of excessive NO
generated by the increased NOS1 expression from activated
neurons, which plays an important role in the maintenance of
neuropathic pain trough microglial activation. The activated
microglia promotes the consolidation and progression of neuro-
pathic pain by the up-regulation of several inflammatory pathways
including the NOS2/NO pathway, among others. Thus, the
activation of the HO-1/CO pathway on microglial cells would
control and limit the spreading of this neuroinflammatory process
by regulating the enhanced expression of NOS2. In addition, CO
located in neurons could also participates in the modulation of
neuropathic pain by decreasing the production of NOS1 which
would restrict the activation of microglia and attenuates the
development of neuropathic pain.
This study reports for first time that an interaction between the
CO and NO systems is taking place following sciatic nerve injury.
Our data also reveal that exogenous delivery of CO using CO-
releasing molecules or increasing the endogenous CO production
with cobalt protoporphyrin IX may represent a novel stratagem in
the management of neuropathic pain.
Materials and Methods
Ethics Statement
Animal procedures were conducted in accordance with the
guidelines of the European Communities, Directive 86/609/EEC
regulating animal research and approved by the local ethical
committee of our Institution (Comissio´ d’Etica en l’Experimenta-
cio´ Animal i Humana de la Universitat Auto`noma de Barcelona,
#6266). All efforts were made to minimize animal suffering, and
to reduce the number of animals used.
Animals
In vivo experiments were performed in male NOS2-KO mice
(C57BL/6J background) purchased from Jackson Laboratories
(Bar Harbor, ME, USA) and in WT mice with the same genetic
background (C57BL/6J) acquired from Harlan Laboratories
(Barcelona, Spain). All mice weighing 21 to 25 g were housed
under 12-h/12-h light/dark conditions in a room with controlled
temperature (22uC) and humidity (66%). Animals had free access
to food and water and were used after a minimum of 6 days
acclimatization to the housing conditions. All experiments were
conducted between 9:00 AM and 5:00 PM.
Induction of Neuropathic Pain
Neuropathic pain was induced by chronic constriction of the
sciatic nerve [6]. Briefly, sciatic nerve ligation was performed
under isoflurane anesthesia (3% induction, 2% maintenance). The
biceps femoris and the gluteus superficialis were separated by blunt
dissection, and the right sciatic nerve was exposed. The injury was
produced by tying three ligatures around the sciatic nerve as
described by Bennett and Xie [34]. The ligatures (4/0 silk) were
tied loosely around the nerve with 1 mm spacing, until they
elicited a brief twitch in the respective hindlimb, which prevented
over-tightening of the ligations, taking care to preserve epineural
circulation. Sham-operated mice that underwent exposure of the
right sciatic nerve without ligature were used as controls.
The development of mechanical and thermal allodynia as well
as thermal hyperalgesia was evaluated by using the von Frey
filaments, cold plate and plantar tests, respectively. All animals
were tested in each paradigm before surgery and at 10, 14 and
20 days after sciatic nerve injury.
Nociceptive Behavioral Tests
Mechanical allodynia was quantified by measuring the hind
paw withdrawal response to von Frey filament stimulation. In
brief, animals were placed in a PlexiglasH box (20 cm high, 9 cm
diameter) with a wire grid bottom through which the von Frey
filaments (North Coast Medical, Inc., San Jose, CA, USA) bending
force range from 0.008 to 3.5 g, were applied by using a modified
version of the up–down paradigm, as previously reported by
Chaplan et al [35]. The filament of 0.4 g was used first and the
3.5 g filament was used as a cut-off. Then, the strength of the next
filament was decreased or increased according to the response.
The threshold of response was calculated from the sequence of
filament strength used during the up–down procedure by using an
Excel program (Microsoft Iberia SRL, Barcelona, Spain) that
includes curve fitting of the data. Clear paw withdrawal, shaking
or licking of the paw were considered nociceptive-like responses.
Both ipsilateral and contralateral hind paws were tested. Animals
were allowed to habituate for 1 h before testing in order to allow
an appropriate behavioral immobility.
Thermal hyperalgesia was assessed as previously reported by
Hargreaves et al [36]. Paw withdrawal latency in response to
radiant heat was measured using the plantar test apparatus (Ugo
Basile, Italy). Briefly, mice were placed in Plexiglas boxes (20 cm
high 69 cm diameter) positioned on a glass surface. The heat
source was positioned under the plantar surface of the hind paw
and activated with a light beam intensity, chosen in preliminary
studies to give baseline latencies from 8 to 9 s in control mice. A
cut-off time of 12s was used to prevent tissue damage in absence of
response. The mean paw withdrawal latencies from the ipsilateral
and contralateral hind paws were determined from the average of
3 separate trials, taken at 5 min intervals to prevent thermal
sensitization and behavioral disturbances. Animals were habituat-
ed to the environment for 1 h before the experiment to become
quiet and to allow testing.
Thermal allodynia to cold stimulus was assessed by using the
hot/cold-plate analgesia meter (Ugo Basile, Italy), previously
described by Bennett and Xie [34]. The number of elevations of
each hind paw was recorded in the mice exposed to the cold plate
(460.5uC) for 5 minutes.
Western Blot Analysis
Sham-operated and sciatic nerve-injured mice were sacrificed at
20 days after surgery by cervical dislocation. Tissues from the
ipsilateral lumbar section of spinal cord and dorsal root ganglia (L3
to L5) were removed immediately after sacrifice, frozen in liquid
nitrogen and stored at 280uC until assay. Samples from the spinal
cord and dorsal root ganglia from three to five animals were
pooled into one experimental sample to obtain enough protein
levels for performing the western blot analysis. The HO-1, HO-2,
CD11b/c, NOS1 and NOS2 protein levels were analyzed by
Western blot. Tissues were homogenized in ice-cold lysis buffer
(50 mM Tris?Base, 150 nM NaCl, 1% NP-40, 2 mM EDTA,
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1 mM phenylmethylsulfonyl fluoride, 0.5 Triton X-100, 0.1%
SDS, 1 mM Na3VO4, 25 mM NaF, 0.5% protease inhibitor
cocktail, 1% phosphatase inhibitor cocktail). All reagents were
purchased at Sigma (St. Louis, MO, USA) with the exception of
NP-40 from Calbiochem. The crude homogenate was solubilised
1 hour at 4uC, sonicated for 10 seconds and centrifugated at 4uC
for 15 min at 7006g. The supernatants (50 or 100 mg of total
protein) were mixed with 46 laemmli loading buffer and then
loaded onto 4% stacking/10% separating SDS-polyacrylamide
gels. The proteins were electrophoretically transferred onto PVDF
membrane for 120 minutes for HO-1, HO-2 and CD11b/c or
over night for NOS1 and NOS2 detection, blocked with PBST
+5% nonfat dry milk, and subsequently incubated overnight at
4uC with a polyclonal rabbit anti-HO-1 (1:300, Stressgen, Ann
Arbor, MI), a polyclonal rabbit anti-HO-2 (1:1000, Stressgen, Ann
Arbor, MI), a polyclonal rabbit anti-CD11b/c (1:300, Novus
Biologicals) antibody against the type 3 complement receptor to
detect activated microglial cells [25], a polyclonal rabbit anti-
NOS1 antibody (1:100, BD Transduction Laboratories, San
Diego, CA, USA) or a polyclonal rabbit anti-NOS2 antibody
(1:200, Chemicon, Millipore). The proteins were detected by
a horseradish peroxidase-conjugated anti-rabbit secondary anti-
body (GE Healthcare, Little Chalfont, Buckinghamshire, UK) and
visualized by chemiluminescence reagents provided with the ECL
kit (Amersham Pharmacia Biotech, Piscataway, NJ, USA) and
exposure onto hyperfilm (GE, Healthcare). The intensity of blots
was quantified by densitometry. The membranes were stripped
and reproved with a monoclonal rabbit anti-b-actin antibody
(1:10.000, Sigma, St. Louis, MO, USA) used as a loading control.
Experimental Protocol
In a first set of experiments we assessed the expression of
neuropathic pain by using the mouse model of the chronic
constriction of sciatic nerve previously used by us [6]. After the
habituation period, baseline responses were established in the
following sequence: von Frey filaments, plantar and cold plate
tests. After that neuropathic pain was induced, and WT or NOS2-
KO animals were again tested in each paradigm at days 10, 14
and 20 after surgery. Sham-operated mice were used as controls.
Sciatic nerve-injured or sham-operated WT or NOS2-KO
animals received the intraperitoneal administration of two CO-
RMs (CORM-2 or CORM-3, at 5 mg/kg of body weight twice
a day) [21,27], an HO-1 inducer (CoPP, at 2.5 mg/kg of body
weight twice a day) [37] or vehicle, from days 10 to 20 after
surgery.
In other set of experiments, taking into account the analogous
effects produced by CORM-2 and CORM-3 on the inhibition of
the allodynia and hyperalgesia induced by sciatic nerve injury and
in order to minimize the number of animals used, the protein
levels of HO-1, HO-2, CD11b/c, NOS1 and NOS2 in the
ipsilateral site of the spinal cord and/or dorsal root ganglia from
sciatic nerve-injured WT and NOS2-KO mice at 20 days after
surgery, were only evaluated in CORM-2 and CoPP treated
animals, by using western blot assay. In these experiments sham-
operated mice treated with vehicle have been used as a control.
Drugs
CORM-2 (tricarbonyldichlororuthenium(II)dimer) was pur-
chased from Sigma-Aldrich (St. Louis, MO), CoPP from Frontier
scientific (Livchem GmbH & Co, Frankfurt, Germany) and
CORM-3 (tricarbonylchloro (glycinate)ruthenium (II)) was syn-
thesized as previously described by Motterlini et al. [21]. CORM-
2 and CoPP were dissolved in dimethyl sulfoxide (DMSO; 1%
solution in saline) and CORM-3 in saline. All drugs were freshly
prepared before use and intraperitoneally administered in a final
volume of 10 ml/kg, twice a day. The control group received the
same volume of vehicle.
Statistical Analysis
Data are expressed as mean 6 standard error of the mean
(SEM). For each genotype and test assessed, the comparison of the
effects produced by CORM-2, CORM-3 or CoPP vs. the effects
produced by vehicle in nerve-injured and sham-operated WT or
NOS2-KO mice were evaluated by using a using a three way
ANOVA (surgery, treatment and time as between factors of
variation) followed by the corresponding one way ANOVA and
the Student Newman Keuls test.
Changes in the expression of HO-1, HO-2, CD11b/c, NOS1
and NOS2 in the spinal cord and/or dorsal root ganglia from
sciatic nerve-injured WT and NOS2-KO mice treated with
vehicle, CORM-2 or CoPP were analyzed by using a one way
ANOVA followed by the Student Newman Keuls test. A value of
p,0.05 was considered as a significant.
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